Your session is about to expire
What is Navelbine
VinorelbineThe Generic name of this drug
Treatment SummaryVinorelbine is a chemotherapy drug used to treat breast cancer and non-small cell lung cancer (NSCLC). It was approved by the FDA in the 1990s specifically for NSCLC. Vinorelbine belongs to a group of drugs known as vinca alkaloids, which have been found to improve survival rates in patients with advanced NSCLC. However, treatment with vinorelbine can cause serious side effects. A study was done that showed that genetic mutations can affect how quickly the body clears vinorelbine, with some patients clearing the drug up to 4.3 times faster than others
Vinorelbineis the brand name
Navelbine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vinorelbine
Vinorelbine
2003
22
Approved as Treatment by the FDA
Vinorelbine, otherwise called Vinorelbine, is approved by the FDA for 3 uses which include Locally Advanced Non-Small Cell Lung Cancer and Previously Untreated .Locally Advanced Non-Small Cell Lung Cancer
Used to treat Locally Advanced Non-Small Cell Lung Cancer in combination with Cisplatin
Previously Untreated
Used to treat Previously Untreated in combination with Cisplatin
Malignant Neoplasms
Used to treat Metastatic Non-Small Cell Lung Cancer in combination with Cisplatin
Effectiveness
How Navelbine Affects PatientsVinorelbine is a medication used to fight tumors. It belongs to a group of drugs called vinca-alkaloids, which stop cancer cells from dividing by preventing them from forming the structures needed for cell division.
How Navelbine works in the bodyVinorelbine tartrate is a special type of vinca alkaloid that works to fight cancer. It does this by inhibiting the process of cell division, by attaching to the microtubule proteins in the cell. This prevents cells from dividing and reproducing, resulting in cell death. Vinorelbine also works to activate certain tumor suppressor genes, like p53, and deactivate certain cancer-promoting proteins. It also affects metabolism, respiration, and other essential cell functions. All of these effects together lead to the death of cancerous cells.
When to interrupt dosage
The dosage of Navelbine is contingent upon the diagnosed issue, including Monotherapy, Soft Tissue Sarcoma and Malignant Neoplasms. The quantity of dosage is further dependent upon the administration approach (e.g. Solution - Intravenous or Solution) elucidated in the accompanying table.Condition
Dosage
Administration
Metastatic Breast Cancer
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Monotherapy
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Malignant Neoplasms
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Soft Tissue Sarcoma
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Locally Advanced Non-Small Cell Lung Cancer
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Previously Untreated
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Recurrent Cervical Cancer
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Warnings
There are 20 known major drug interactions with Navelbine.Common Navelbine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Aldosterone.
Navelbine Toxicity & Overdose RiskVinorelbine has been linked to a variety of potential side effects, including decreased white blood cell count, infections, anemia, tingling or numbness in the extremities, hair loss, difficulty breathing, nausea, constipation, vomiting, diarrhea, fatigue, abdominal pain, chest pain, jaw pain, muscle aches, joint aches, headaches, difficulty swallowing, skin rash, bleeding in the bladder, and abnormal production of a hormone. It may also affect the chromosomes in the body. These side effects vary in severity and some may be life-threatening.
Navelbine Novel Uses: Which Conditions Have a Clinical Trial Featuring Navelbine?
155 active studies are being conducted to assess the potential of Navelbine as a Monotherapy, Previously Untreated and Soft Tissue Sarcoma Treatment.Condition
Clinical Trials
Trial Phases
Soft Tissue Sarcoma
67 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Metastatic Breast Cancer
95 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Recurrent Cervical Cancer
0 Actively Recruiting
Monotherapy
1 Actively Recruiting
Phase 1, Phase 2
Locally Advanced Non-Small Cell Lung Cancer
13 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Malignant Neoplasms
12 Actively Recruiting
Phase 3, Phase 1, Phase 2
Previously Untreated
0 Actively Recruiting
Navelbine Reviews: What are patients saying about Navelbine?
5Patient Review
10/23/2013 Navelbine was fantastic for my bone and soft tissue cancer in my neck. I had weekly treatments for six months with very minimal side effects-- just some leg fatigue at the six month mark. I stopped taking it because of the leg pain, but if my current treatment stops working, I can go back on Navelbine. Right now, my cancer is stable.
5Patient Review
7/20/2013 Navelbine was really the first treatment that helped me. I had bone mets from breast cancer and the pain was unbearable. But after beginning this medication, I felt so much better almost immediately!
5Patient Review
7/8/2009 My mom has been battling lung cancer for over 10 years and we've tried a lot of different treatments. This is one of the last options, but it's working really well for her. She doesn't have many side effects and is able to live a normal life including going shopping and exercising twice a week!
5Patient Review
1/22/2009 I've been taking this medication for almost four years, and it's been working great! The only downside is the side effects, but they're manageable.
4.7Patient Review
6/24/2013 I'm currently on my fifth cycle of this medication, and the biggest complaint I have is the fatigue. The nausea is easily dealt with a zofran/ativan combo, but the fatigue has been tough to manage. However, it's worth it because this medication has kept my cancer from growing (it's stable).
4.7Patient Review
6/1/2017 I've now completed five out of six cycles and the results have been great so far. The main side effects I've experienced are constipation, hair thinning, and fatigue. All things considered, it's been relatively easy to tolerate.
4.3Patient Review
8/14/2008 This treatment has been working well for my mother during her cancer battle. She doesn't experience any nausea, but her blood pressure can be all over the place. Additionally, she's lost hair and is very tired.
4.3Patient Review
6/26/2008 I had a really bad headache, stomach pain, and feeling weak. I think my blood pressure was low because I felt confused, too.
4Patient Review
4/15/2009 I take this once a month with few side effects and have been in remission since I started.
3Patient Review
3/17/2011 My husband has been taking this medication for two months with little to no relief from his symptoms. He was diagnosed in October 2009 and we're hoping for the best, but so far this treatment hasn't helped much.
3Patient Review
1/14/2009 I was really struggling until I stopped taking this.
3Patient Review
2/22/20081.7Patient Review
3/25/2012 This medication caused a significant decrease in my white blood cells, and I also experienced a lot of bone pain and wheezing.
1.3Patient Review
1/17/2010 After developing a severe chest infection, I started to experience extreme gastritis and weakness. The metastases were also extremely severe.
1Patient Review
10/29/2009 I'm looking for information about
Patient Q&A Section about navelbine
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How often is Navelbine given?
"The dosage of NAVELBINE should be 30 mg/m2 given as an IV either as an injection or an infusion over 6-10 minutes. This should be done once a week in combination with cisplatin 120 mg/m2 given on days 1 and 29. This process should be repeated every 6 weeks."
Answered by AI
How effective is Navelbine?
"A phase 2 clinical trial that is studying the effectiveness of navelbine (vinorelbine) as a single-agent first-line treatment is showing a partial response rate of 24%, a stable disease rate of 55% with 21% of patients experiencing disease progression during treatment. This means that out of 100 patients treated with this drug, 24% saw their cancer shrink, 55% saw their cancer stay the same, and 21% saw their cancer grow."
Answered by AI
Does Navelbine cause neuropathy?
"The most common adverse reactions to NAVELBINE when used as a single agent include low white blood cell count, low neutrophil count, low hemoglobin, increased AST, nausea, vomiting, constipation, fatigue, reaction at the injection site, and peripheral neuropathy."
Answered by AI
What is Navelbine used to treat?
"Vinorelbine is a chemotherapy drug used for the treatment of breast cancer. Navelbine is the brand name for this drug."
Answered by AI